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JOURNAL OF CLINICAL ONCOLOGY C O R R E S P O N D E N C E
Therapy for Secondary CNS
Involvement inMalignant Lymphomas:
No Standard Yet!
TO THE EDITOR: The prognosis of secondary CNS involvement
in systemic lymphomas (secondary CNS lymphoma, SCNSL) is
poor, and the optimal treatment remains to be established. Because
of the rarity of SCNSL and the lack of prospective trials, the level of
evidence guiding therapy is low. Limited data suggest that intensive
systemic chemotherapy, followed by high-dose chemotherapy and
autologous stem-cell transplant (HD-ASCT), is the only potentially
curative approach.
In their recent article in Journal of Clinical Oncology, Ferreri et al1
report on a phase II trial of 38 patients with SCNSL treated with an
antimetabolite-based chemotherapy followed by HD-ASCT. For all
patients, the 2-year event-free survival (EFS; primary end point) was
50% and the 5-year EFSwas 40%. The 5-year overall survival (OS) was
41% for all patients and 68% for those who completedHD-ASCT. The
authors conclude that this regimen should be considered as the new
standard of care for patients with SCNSL. This is a well-conducted and
concisely reported trial, but there are several aspects that warrant
commentary.
First, the complete omission of anthracyclines and vinca
alkaloids, uniformly accepted as standard therapy of aggressive B-cell
lymphomas, likely led to the undertreatment of chemotherapy-na¨ıve
patients, for whom rituximab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone–like protocols, enriched by CNS-
penetrating drugs such as high-dose methotrexate, may be a
preferable treatment option, as currently practiced by others.
Secondly, study patients were heterogeneous with respect to
histology (diffuse large B-cell [n 5 32], mantle-cell [n 5 3], and
follicular [n 5 3] lymphoma). The authors’ assumption that his-
tology does not affect outcome in SCNSL has never been sub-
stantiated. Moreover, both therapy-na¨ıve patients with CNS
involvement at diagnosis (n 5 16) and pretreated patients with
SCNSL at relapse (n5 22) were included, and there was a wide range
between the time of lymphoma diagnosis and CNS involvement (0 to
69 months). Ferreri et al1 contend that the outcome of SCNSL is
similar, regardless of histology and pretreatment. However, because of
the small sample size, these assumptions cannot be corroborated. For
example, the difference in 5-year OS between patients with delayed
SCNSL (5-year OS, 45%) and those with SCNSL at diagnosis (5-year
OS, 36%) suggests a better prognosis for the delayed group (relative
risk, 1.21); however, the precision of this estimate is low (95% CI,
0.56 to 2.65). Also, because 58% of patients (all with delayed SCNSL)
received a wide variety of previous treatments further heterogeneity
and potential bias were introduced.
Most importantly, despite the valuable information this trial
provides, it is uncontrolled, and the primary outcomemeasure (2-year
EFS) was assessed by unblinded treating investigators. Both of these
features demand the assignment of class IV evidence for this study,
which can never be the basis of standard-of-care decisions. Even
ignoring this important issue, the trial failed to achieve its predeﬁned
primary outcome (a 2-year EFS of 60%). To demonstrate a convincing
treatment effect using the same primary outcome measure, the same
study parameters (signiﬁcance of 0.05, power of 80%, uninteresting
response rate of 40%) and the actual 2-year EFS seen in this trial
(50%), 154 patients would have been required using the Fleming
design used by the authors.
The third point concerns the feasibility of the proposed therapy.
Ferreri et al1 state that the protocol was tolerable, notwithstanding
the reported dropout rate of 47% (18 of 38 patients). Moreover, it is
stated that 123 (81%) of the 152 planned cycles were administered.
However, in that HD-ASCTwas included as planned therapy, it seems
that only 65% (123 of 190) of planned cycles were administered.
The fourth point of concern pertains to the toxicity of the
treatment. The toxicity-related death rate of 11% (95% CI, 4.2%
to 24.1%) is formidable. In addition, three patients had grade 3 or
4 bleeding, two had Aspergillus pneumonia, one patient each had
Guillain-Barre´ syndrome and a secondary malignancy, and an
unspeciﬁed number of patients manifested cytomegalovirus reac-
tivation. Ferreri et al1 state that no late neurotoxicity was observed;
however, the method and timing of evaluation are not stated.
The study by Korfel et al2 illustrates that a relatively homo-
genous group of patients with SCNSL can be recruited and treated in
a prospective multicenter study (all patients had aggressive lym-
phoma with SCNSL at relapse and were pretreated—the majority
with rituximab plus cyclophosphamide, doxorubicin, vincristine,
and prednisone); it also demonstrates that a chemotherapy-only
regimen is feasible in patients with SCNSL and is associated with a
relatively low dropout rate (80% completed the study protocol),
and that a 2-year EFS of 50% can be achieved with an acceptable
therapy-related death rate of 3%.
The protocol reported by Ferreri et al1 deserves further eval-
uation in awell-deﬁned,more homogeneous patient population and
with a predeﬁned monitoring protocol for toxicity. Considering this
regimen to be the standard for routine patient care and in the design
of future studies seems premature.
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